Historical idxx News Stories

IDEXX Soars: Diagnostics + Software Drive Rally Q4

IDEXX Laboratories (IDXX) extended its strong 2025 run this week as investors cheered robust diagnostic consumables and accelerating adoption of software tools like Vello and PIMS integrations. YTD gains near 76% reflect concrete growth levers—recurring companion-animal diagnostics revenue, higher utilization from installed instruments, and expanding recurring software bookings—while peers such as Zoetis showed relative weakness. This article summarizes the key data points from the past week, explains why they matter for IDXX’s outlook, and highlights operational and investor considerations.

IDEXX Q3 Beat Lifts Water & Livestock Testing Now!

IDEXX reported strong Q3 2025 results with $1.105B revenue, raised full-year guidance, and notable strength in livestock and water testing; Zoetis’ weaker print contrasts the diagnostic-driven momentum, reinforcing IDEXX’s differentiated exposure in veterinary testing.

IDEXX Q3 Beat, Guidance Up — Dip = Buying Chance!!

IDEXX reported a strong Q3 with 13% revenue growth, raised full‑year guidance and recorded a surge in instrument placements—yet the stock pulled back modestly. Contrast with Zoetis' livestock weakness suggests IDEXX's diagnostics exposure could be a durable advantage. This article breaks down the numbers, market reaction, and investor takeaways.

IDEXX Surge: InVue Install Boom, Catalyst Cortisol

IDEXX reported a sharp uptick in InVue Dx installations and raised guidance after strong quarterly results; new Catalyst Cortisol testing and multiple analyst price-target increases have reinforced investor confidence in IDXX’s diagnostic growth trajectory.

IDEXX Surge: Cancer Dx Launch, Analyst Upside Now!!

IDEXX’s recent week saw the launch of an affordable Cancer Dx canine lymphoma panel and several analyst upgrades, boosting sentiment. Offsetting this are FX headwinds, rising costs and cooling trading volume — key factors investors should watch.